2019 CYIR Finalized

19 SARCOIDOSIS PHENOTYPES OF SARCOIDOSIS Schupp JC, Freitag-Wolf S, Bargagli E, Mihailović-Vučinić V, Rottoli P, Grubanovic A, Müller A, Jochens A, Tittmann L, Schnerch J, Olivieri C, Fischer A, Jovanovic D, Filipovic S, Videnovic-Ivanovic J, Bresser P, Jonkers R, O’Reilly K, Ho LP, Gaede KI, Zabel P, Dubaniewicz A, Marshall B, Kieszko R, Milanowski J, Günther A, Weihrich A, Petrek M, Kolek V, Keane MP, O’Beirne S, Donnelly S, Haraldsdottir SO, Jorundsdottir KB, Costabel U, Bonella F, Wallaert B, Grah C, Peroš-Golubičić T, Luisetti M, Kadija Z, Pabst S, Grohé C, Strausz J, Vašáková M, Sterclova M, Millar A, Homolka J, Slováková A, Kendrick Y, Crawshaw A, Wuyts W, Spencer L, Pfeifer M, Valeyre D, Poletti V, Wirtz H, Prasse A, Schreiber S, Krawczak M, Müller-Quernheim J. Phenotypes of organ involvement in sarcoidosis. Eur Respir J 2018; 51(1): pii: 1700991 Summary The article describes the results of the baseline phenotype module of a European multicenter study to investigate the influence of genotype on disease phenotypes in sarcoid- osis. The study cohort comprised 2163 Caucasian patients with sarcoidosis who were phenotyped at 31 centers according to a standardized protocol. The authors found that patients with acute onset were mainly female, young and of Scadding type I or II. Female patients showed a significantly higher frequency of eye and skin involvement and reported more often fatigue. Based on multidimen- sional correspondence analysis and subsequent cluster analysis, patients could be stratified into five distinct, yet undescribed, subgroups according to predominant organ involvement: 1) abdominal organ involvement, 2) ocular-cardiac-cutaneous-central nervous system disease involvement, 3) musculoskeletal-cutaneous involvement, 4) pulmonary and intrathoracic lymph node involvement, and 5) extrapulmonary involvement. The authors concluded that these new phenotypes can be used in clinical and bio- medical studies to obtain homogenous and clearly defined sub-cohorts of sarcoidosis patients. The results will also be used for their future genotype-phenotype studies. Comments 1. The five new clinical phenotypes might be useful to recruit homogenous cohorts in future biomedical studies. 2. However, the phenotypes are probably only applicable in Caucasians and might not be useful in other ethnicities. 3. Unfortunately there was no data on types of skin involvement, so it was uncertain in which phenotype classical Löfgren syn- drome is concealed. 4. Investigators were mainly pulmonologists, so an overrepresen- tation of pulmonary sarcoidosis is possible. 5. All study sites were tertiary referral centers, so an overrepre- sentation of patients with complicated, advanced sarcoidosis is likely. MORTALITY OF SARCOIDOSIS Rossides M, Kullberg S, Askling J, Eklund A, Grunewald J, Arkema EV. Sarcoidosis mortality in Sweden: a population- based cohort study. Eur Respir J 2018; 51(2): pii:1701815. Summary The article describes the results of a population-based cohort study into sarcoidosis mortality, taking into account disease heterogeneity. Individuals with incident sarcoidosis (n=8207) were identified from the Swedish National Patient Register using ICD codes (2003‒2013). In a subset, cases receiving treatment ± 3 months from diagnosis were identi- fied from the Prescribed Drug Register. Non-sarcoidosis comparators from the general population were matched to cases 10:1 on birth year, sex and county. Individuals were followed for all-cause death in the Cause of Death Register. Adjusted mortality rates, rate differences and hazard ratios (HRs) were estimated, stratifying by age, sex and treatment status. The mortality rate was 11.0 per 1000 person-years in sarcoidosis versus 6.7 in comparators (rate difference 2.7 per 1000 person-years). The HR for death was 1.61 (95% CI 1.47‒1.76), with no large variation by age or sex. For cases not receiving treatment within the first 3 months, the HR was 1.13 (95% CI 0.94‒1.35). For those receiving treatment HR was 2.34 (95% CI 1.99‒2.75). Individuals with sarcoidosis are therefore at a higher risk of death com- pared to the general population; especially those whose disease needs treatment around diagnosis have a two-fold increased risk of death. Comments 1. Strength of this study is the use of high-quality registers with excellent coverage of the entire Swedish population. 2. The study shows that individuals with sarcoidosis who do not receive treatment at diagnosis have only a marginally increased risk of death. SARCOIDOSIS Jan C. Grutters, MD, PhD St. Antonius Hospital and University Medical Center Utrecht Department of Pulmonology Nieuwegein, The Netherlands MONDAY, MAY 20

RkJQdWJsaXNoZXIy MTM1ODMw